Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Colorectal Cancer Clinical Trials

A listing of Colorectal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (93) clinical trials

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced GI tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment. Once the dose is ...

Phase

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of CPI-613 (6,8-bis[benzylthio]octanoic acid), when used in combination with 5-FU (fluorouracil), in patients with non-resectable metastatic colorectal cancer who have failed FOLFOX (leucovorin calcium, fluorouracil and oxaliplatin), FOLFIRI (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) and, if Kirsten rat sarcoma viral ...

Phase

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic Ovarian and Colorectal Cancers

This is a prospective, non-randomised, open label, Phase I, dose escalation study of plerixafor (MozobilTM) in patients with histological documentation of advanced pancreatic, high grade serous ovarian or colorectal adenocarcinoma. We will investigate the feasibility of administering plerixafor in terms of safety, and will try to identify the proof of ...

Phase

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

This is a phase 1b feasibility study to evaluate the use of PD-1 blockade in combination with ablative radiotherapy for the treatment of metastatic colorectal cancer (CRC). This study will examine the sequential combination of stereotactic body radiotherapy (SBRT) and pembrolizumab for patients for whom the goal is eradicating all ...

Phase

A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

The Screening period is 4 weeks prior to study enrollment. This study has 2 Cohorts. Cohort Triple Negative Breast Cancer and Cohort 2: Colorectal Cancer. These cohorts will enroll in parallel. There will be a Safety Follow-up period and a Long Term Follow-up period. Drug Administration: The participants will receive ...

Phase

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

This is a one-arm study, which will be conducted in 2 parts: A dose-escalation part to determine the Maximum Tolerated Dose (MTD) of S 95005 in combination with oxaliplatin. An expansion part in patients treated at the recommended dose defined in the dose escalation part of this study to evaluate ...

Phase

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

PRIMARY OBJECTIVES: I. Determine the recommended phase II dose for the combination of XL888 and pembrolizumab. SECONDARY OBJECTIVES: I. Define the toxicity profile of the combination of XL888 and pembrolizumab. II. Evaluate the activity of the combination of XL888 and pembrolizumab in previously treated patients with gastrointestinal tumors. TERTIARY OBJECTIVES: ...

Phase

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22). Treatment with pembrolizumab / maraviroc combination will continue until progressive disease (PD), unacceptable adverse events (AEs), intercurrent illness that ...

Phase

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus FOLFIRI to evaluate the safety, efficacy, and pharmacokinetics of OMP-305B83 in combination with FOLFIRI in patients with metastatic Colorectal Cancer. This study consists of a screening period, a treatment period, and a post-treatment follow-up period in ...

Phase

Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO)

This is a Phase 1, open-label, single-arm, multicenter study to evaluate the safety, tolerability, and immunogenicity of a single subcutaneous (SC) injection of PolyPEPI1018 as an add-on immunotherapy to the standard-of-care maintenance therapy in approximately 10 subjects with mCRC. The study is composed of a 3week Screening Period, the administration ...

Phase